Dose-finding of Semaglutide Administered Subcutaneously Once Daily Versus Placebo and Liraglutide in Subjects With Type 2 Diabetes

Summary

This trial is conducted globally. The aim of this trial is to investigate dose-finding of semaglutide administered subcutaneously once daily versus placebo and liraglutide in subjects with type 2 diabetes

Timeline

Start

2015-09-21

Primary completion

2016-10-13

Completion

2016-10-13

Outcome

Met primary endpoint

registry analysis (other test); Semaglutide 0.05 mg/Day vs Placebo; p <0.0001; Treatment difference -1.04 (95% CI -1.30 to -0.77); Mixed Models Analysis NCT02461589 ↗

paper all P < 0.001 in favor of volume-matched semaglutide dose PMID 30026333 ↗

Publications

• Results Lingvay I, Desouza CV, Lalic KS, Rose L, Hansen T, Zacho J, Pieber TR. A 26-Week Randomized Controlled Trial of Semaglutide Once Daily Versus Liraglutide and Placebo in Patients With Type 2 Diabetes Suboptimally Controlled on Diet and Exercise With or Without Metformin. Diabetes Care. 2018 Sep;41(9):1926-1937. doi: 10.2337/dc17-2381. Epub 2018 Jul 19.

Drugs

Evaluation	Drug	Modality	Dose	Route
Comparator	Liraglutide	Peptide	0.3 mg	Subcutaneous
Comparator	Liraglutide	Peptide	0.6 mg	Subcutaneous
Comparator	Liraglutide	Peptide	1.2 mg	Subcutaneous
Comparator	Liraglutide	Peptide	1.8 mg	Subcutaneous
Subject	Semaglutide	Peptide	0.05 mg	Subcutaneous
Subject	Semaglutide	Peptide	0.1 mg	Subcutaneous
Subject	Semaglutide	Peptide	0.2 mg	Subcutaneous
Subject	Semaglutide	Peptide	0.3 mg	Subcutaneous

Indications